ORIF Versus CRIF of Completely Displaced and Rotated Lateral Condylar Fractures of the Humerus in Children
Launched by GUANGZHOU WOMEN AND CHILDREN'S MEDICAL CENTER · Nov 18, 2020
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Lateral condylar humerus fractures are the second most common elbow fracture in children, accounting for approximately 17-20% of pediatric elbow fractures. Jakob et al. first described a novel classification based on the presence of cartilage bridging. It was modified by Foster et al. who identified the differences in outcomes between fractures with \< 2 mm and ≥ 2 mm displacement. most surgeons preferred open reduction and internal fixation (ORIF) to insure anatomic reduction of these unstable intra-articular fractures. Only a few reports have focused on closed reduction and Percutaneous P...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • completely displaced and rotated lateral condyle fractures of the humerus (Jakob Stage 3)
- Exclusion Criteria:
- • - presented more than 7 days after the fracture , Capitulum humerus cannot be clearly identified on X-ray, had experienced a previous lateral condyle fractures on the same limbs, pathological fracture, open fracture, Combined with other fractures at the same time,
About Guangzhou Women And Children's Medical Center
Guangzhou Women and Children's Medical Center is a leading healthcare institution dedicated to advancing the health and well-being of women and children through comprehensive medical services, research, and education. As a prominent clinical trial sponsor, the center focuses on innovative studies aimed at improving maternal and pediatric health outcomes. With a commitment to evidence-based practices and collaborative partnerships, the center strives to contribute to the global body of medical knowledge while ensuring the highest standards of patient care and ethical research practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
Hongwen Xu, doctor
Principal Investigator
Guangzhou Women & Children Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials